Literature DB >> 15160906

The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL).

Tryfonia Mainou-Fowler1, Helen M Dignum, Stephen J Proctor, Geoffrey P Summerfield.   

Abstract

A large number of prognostic factors are available to help predict the outcome of patients who present with B-cell chronic lymphocytic leukemia (B-CLL). These include clinical stage, leukemic cell morphology, lymphocyte doubling time, the pattern of infiltration in bone marrow trephine biopsies, cytogenetic abnormalities, p53 function and serum factors such as beta-2 microglobulin. Two recently described major prognostic factors are immunoglobulin heavy chain variable region (IgVH) mutation status and cell membrane expression of CD38. These are both highly significant independent prognostic factors, but are not closely correlated. Whereas IgVH mutational status is a time consuming and demanding technique, only available in a limited number of centres, CD38 expression by flow cytometry is relatively simple and rapidly obtained in most diagnostic laboratories. The predictive value of CD38 expression is enhanced by measurement of antigen density in terms of antibody binding capacity (ABC) rather than as the percentage of cells expressing the antigen. ABC correlates closely with relative median fluorescence (RMF), a parameter which is even more simply and cheaply obtained by flow cytometry. One of these methods of determining CD38 expression should be employed routinely. Recent work suggests that membrane ZAP-70 expression determined by flow cytometry will prove to be an accurate proxy for IgVH mutational status and this assay will be within the reach of any laboratory skilled in flow cytometry. The combination of ZAP-70 expression, CD38 antigen density, p53 function and the concentration of serum factors such as soluble CD23, is likely to provide extremely accurate prognostic information in future studies. This will assist in identifying Stage A patients who may benfit from early and/or more intensive treatment, as well as Stage B and C patients who may require alternative treatment strategies at the outset.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160906     DOI: 10.1080/1042819032000141275

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

2.  B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.

Authors:  Elena Sabattini; Rocio Orduz; Cristina Campidelli; Pier Luigi Zinzani; Vincenzo Callea; Simona Zupo; Giovanna Cutrona; Fortunato Morabito; Manlio Ferrarini; Stefano Pileri
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

Review 3.  Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis.

Authors:  Marcus Kremer; Leticia Quintanilla-Martínez; Jörg Nährig; Christoph von Schilling; Falko Fend
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

4.  Isolation of hematopoietic stem cells and the effect of CD38 expression during the early erythroid progenitor cell development process.

Authors:  Işil Albenız; Leyla Türker-Şener; Aycan Baş; Ibrahim Kalelıoğlu; Rüstem Nurten
Journal:  Oncol Lett       Date:  2011-10-21       Impact factor: 2.967

5.  Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology.

Authors:  Sona Peková; Ludmila Bezdícková; Lukás Smolej; Tomás Kozák; Ivana Hochová; Pavel Zák; Lucie Tomsíková; Miroslav Průcha
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  Drp1 mediates caspase-independent type III cell death in normal and leukemic cells.

Authors:  Marlène Bras; Victor J Yuste; Gaël Roué; Sandrine Barbier; Patricia Sancho; Clémence Virely; Manuel Rubio; Sylvie Baudet; Josep E Esquerda; Hélène Merle-Béral; Marika Sarfati; Santos A Susin
Journal:  Mol Cell Biol       Date:  2007-08-06       Impact factor: 4.272

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.